Safety and Pharmacokinetics Study of DWC20155 and DWC20156 in Healthy Subjects

Daewoong Pharmaceutical Co. LTD.52 enrolled

Overview

The purpose of this study to Compare the safety and pharmacokinetics between co-administration and fixed dose combination of DWC20155 and DWC20156 in healthy subjects

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

Co-administration of DWC20155 and DWC20156DRUG

DWJ1366 Tab.DRUG

Eligibility

Sex: ALLMin age: 19 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * BMI ≥ 18.5 and ≤ 27.0 kg/m2. * No clinically significant findings * Age 19-55 years at screening Exclusion Criteria: * Who has allergy to investigational product

Locations (1)

Busan Paik Hospital

Busan, South Korea

Outcomes

Primary Outcomes

Maximum Plasma Concentration (Cmax)

Time frame: 0-24 hours

Area under the plasma concentration versus time curve (AUC)

Time frame: 0-24 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.